Pretreatment with probiotics (Bacillus safensis NMCC-189 and Bacillus clausii) prevents epileptogenesis in mice via modulation of BBB integrity, oxidative stress, and neurotransmitter balance.
Maryam Khan Sherwani, Jehan Zeb Khan, Shakira Ghazanfar, Fahim Hilal, Rimsha Noor, Muhammad Khalid Tipu
{"title":"Pretreatment with probiotics (Bacillus safensis NMCC-189 and Bacillus clausii) prevents epileptogenesis in mice via modulation of BBB integrity, oxidative stress, and neurotransmitter balance.","authors":"Maryam Khan Sherwani, Jehan Zeb Khan, Shakira Ghazanfar, Fahim Hilal, Rimsha Noor, Muhammad Khalid Tipu","doi":"10.1007/s10787-025-01990-w","DOIUrl":null,"url":null,"abstract":"<p><p>Epilepsy remains a difficult neurological condition to treat using conventional therapies. Emerging evidence links gut microbiota to the onset and progression of neurological disorders, including epilepsy. In this study, pretreatment with Bacillus safensis NMCC-189 and Bacillus clausii (probiotics) on epileptogenesis was evaluated. The probiotics were administered orally (10<sup>8</sup> CFU/ml/day) for 14 days, followed by PTZ administration (60 mg/kg i.p) on day 14. The colon length, biochemical/microbiological analysis of fecal matter with oxidative stress markers, confirmed the colonization of the colon with the bacterium in the mice and improved colon health. The mice supplemented with the probiotics bacteria showed significant anticonvulsant effects via delaying onset, reducing severity and duration of the seizures with no mortality in comparison to the non-supplemented PTZ-kindled mice. Protective action in the supplemented mice can be explained by reduced oxidative stress in the brain tissue. Moreover, RT-PCR results showed that prior administration of Bacillus safensis NMCC-189 and Bacillus clausii successfully restored the expression of tight junction (ZO-1, Occludin, Claudin), and normalized glutamatergic (NR1, NR2A, NR2B, mGluR1, GluA1, GluA2) and GABAergic (GABRA1, GABRB1) gene expression altered by PTZ administration, indicating strong neuroprotective and barrier-preserving effects. These findings highlight the potential of probiotics to mitigate excitotoxicity, restore neurotransmitter balance, and protect epithelial and blood-brain barriers in epilepsy. This study highlights Bacillus safensis NMCC-189 and Bacillus clausii as promising probiotics that modulate gut microbiota and exhibit neuroprotective effects, targeting key mechanisms of epileptogenesis. Furthermore, being part of microbial flora, these probiotics lack any side effects, unlike traditional anti-epileptic drugs.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01990-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Epilepsy remains a difficult neurological condition to treat using conventional therapies. Emerging evidence links gut microbiota to the onset and progression of neurological disorders, including epilepsy. In this study, pretreatment with Bacillus safensis NMCC-189 and Bacillus clausii (probiotics) on epileptogenesis was evaluated. The probiotics were administered orally (108 CFU/ml/day) for 14 days, followed by PTZ administration (60 mg/kg i.p) on day 14. The colon length, biochemical/microbiological analysis of fecal matter with oxidative stress markers, confirmed the colonization of the colon with the bacterium in the mice and improved colon health. The mice supplemented with the probiotics bacteria showed significant anticonvulsant effects via delaying onset, reducing severity and duration of the seizures with no mortality in comparison to the non-supplemented PTZ-kindled mice. Protective action in the supplemented mice can be explained by reduced oxidative stress in the brain tissue. Moreover, RT-PCR results showed that prior administration of Bacillus safensis NMCC-189 and Bacillus clausii successfully restored the expression of tight junction (ZO-1, Occludin, Claudin), and normalized glutamatergic (NR1, NR2A, NR2B, mGluR1, GluA1, GluA2) and GABAergic (GABRA1, GABRB1) gene expression altered by PTZ administration, indicating strong neuroprotective and barrier-preserving effects. These findings highlight the potential of probiotics to mitigate excitotoxicity, restore neurotransmitter balance, and protect epithelial and blood-brain barriers in epilepsy. This study highlights Bacillus safensis NMCC-189 and Bacillus clausii as promising probiotics that modulate gut microbiota and exhibit neuroprotective effects, targeting key mechanisms of epileptogenesis. Furthermore, being part of microbial flora, these probiotics lack any side effects, unlike traditional anti-epileptic drugs.
期刊介绍:
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:
-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states
-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs
-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents
-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain
-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs
-Muscle-immune interactions during inflammation [...]